Why the study?
Does serial assessment of left ventricular ejection fraction using quantitative radionuclide angiocardiography predict doxorubicin-induced congestive heart failure in cancer patients?
Population
55 patients receiving doxorubicin for treatment of cancer
Design
Cohort
Authors
Loading...
Serial LVEF monitoring may flag doxorubicin cardiotoxicity risk before heart failure; leaves open whether routine use improves outcomes.
Does serial assessment of left ventricular ejection fraction using quantitative radionuclide angiocardiography predict doxorubicin-induced congestive heart failure in cancer patients?
Serial monitoring of LVEF using radionuclide angiocardiography can identify moderate cardiotoxicity before clinical heart failure develops in patients receiving doxorubicin.
Alexander et al. (1979) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: